✦ LIBER ✦

Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma

✍ Scribed by D. J. Hovgaard; B. T. Mortensen; N. I. Nissen

Book ID: 114714253
Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 595 KB
Volume: 91
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.1995.tb05305.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of interleukin-3 following chemo

Effects of interleukin-3 following chemotherapy of non-Hodgkin's lymphoma. A prospective, controlled phase I/II study.

✍ D. J. Hovgaard; N. I. Nissen 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 681 KB

Modulation of the Systemic Inflammatory

Modulation of the Systemic Inflammatory response By Recombinant Human Interleukin-11: A Prospective Randomized Masked Placebo Controlled Clinical Study in Patients with Acute Myeloid Or Lymphoblastic Leukaemia and Non-Hodgkin's Lymphoma

✍ Michael Ellis; Ulla Hedstrom; Basel Al-Ramadi; Chris Frampton; Hussain Alizadeh; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 38 KB

A phase II trial of human recombinant ln

A phase II trial of human recombinant lnterleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study

✍ Madeline Bauer; Gregory H. Reaman; Jacquelyn A. Hank; Mitchell S. Cairo; Peter A 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 619 KB

A phase I trial to assess the value of r

A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (r-MetHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL)

✍ G. M. Smith; J. A. Child; M. H. Cullen; N. P. Bailey; C. M. Woodruffe; J. Fletch 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 571 KB

In a multi-centre phase I study we investigated the possibility of reducing the interval between courses of standard CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m', vincristine 2 mgs day 1, and prednisolone 40mglm' days 1-8) from 21 days to 15 days and then 10 days using granulocyte colony s

A Randomized Phase III Study of Gemcitab

A Randomized Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin as Salvage Chemotherapy Followed by Posttransplantation Rituximab Maintenance Therapy Versus Observation for Treatment of Aggressive B-Cell and T-Cell Non-Hodgkin's Lymphoma

✍ Crump, Michael; Shepherd, Lois; Lin, Boris 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 108 KB